Cephalon Submits Supplemental New Drug Application For FENTORA

Cephalon, Inc. (Nasdaq: CEPH) announced it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market FENTORA(R) (fentanyl buccal tablet) [C-II] for the management of breakthrough pain in opioid tolerant patients with chronic pain conditions. Breakthrough pain is characterized by its rapid onset, moderate-to-severe intensity, and relatively short duration. [click link for full article]

More: continued here

Filed under: Pain / Anesthetics on November 12th, 2007